

Dried blood spot HIV-1 RNA quantification: A useful tool for viral load monitoring among HIV-infected individuals in India

Ujjwal Neogi, Soham Gupta, Rashmi Rodridges, Pravat Nalini Sahoo, Shwetha D. Rao, Bharat B. Rewari*, Suresh Shastri*, Ayesha De Costa** & Anita Shet

*St. John's National Academy of Health Sciences, Bangalore, *National AIDS Control Organization, New Delhi & **Division of Global Health (IHCAR), Karolinska Institutet, Stockholm, Sweden*

Received November 21, 2011

Background & objectives: Monitoring of HIV-infected individuals on antiretroviral treatment (ART) ideally requires periodic viral load measurements to ascertain adequate response to treatment. While plasma viral load monitoring is widely available in high-income settings, it is rarely used in resource-limited regions because of high cost and need for sophisticated sample transport. Dried blood spot (DBS) as source specimens for viral load measurement has shown promise as an alternative to plasma specimens and is likely to be a useful tool for Indian settings. The present study was undertaken to investigate the performance of DBS in HIV-1 RNA quantification against the standard plasma viral load assay.

Methods: Between April-June 2011, 130 samples were collected from HIV-1-infected (n=125) and non-infected (n=5) individuals in two district clinics in southern India. HIV-1 RNA quantification was performed from DBS and plasma using Abbott m2000rt system after manual RNA extraction. Statistical analysis included correlation, regression and Bland-Altman analysis.

Results: The sensitivity of DBS viral load was 97 per cent with viral loads $>3.0 \log_{10}$ copies/ml. Measurable viral load ($>3.0 \log_{10}$ copies/ml) results obtained for the 74 paired plasma-DBS samples showed positive correlation between both the assays ($r=0.96$). For clinically acceptable viral load threshold values of $>5,000$ copies/ml, Bland-Altman plots showed acceptable limits of agreement (-0.21 to $+0.8 \log_{10}$ copies/ml). The mean difference was $0.29 \log_{10}$ copies/ml. The cost of DBS was \$2.67 lower compared to conventional plasma viral load measurement in the setting.

Interpretation & conclusions: The significant positive correlation with standard plasma-based assay and lower cost of DBS viral load monitoring suggest that DBS sampling can be a feasible and economical means of viral load monitoring in HIV-infected individual in India and in other resource-limited settings globally.

Key words Dried blood spot - HIV - India - public health - resource-limited settings - viral load

A rapid scale up of the national antiretroviral treatment programme in India initiated in April 2004, has ensured that as of March 2011, over 420,000 people living with HIV infection are currently on first-line antiretroviral treatment (ART) free of cost in the public sector¹. The WHO has recommended using clinical monitoring and CD4 measurement as an alternative in resource-limited settings, however, several studies have reported poor sensitivity of these methods in the detection of virological failure^{2,3}. Thus, patients in these settings run the risk of being treated with failing regimens and accumulating drug resistant mutant viruses, thus restricting treatment options further and reducing the chance of complete viral suppression even when switched to second-line treatment in the future. Given this situation, it becomes important to explore a feasible viral load measurement procedure that works in low income settings. An alternative strategy of viral load measurement using dried blood spot (DBS) has shown promise as a reliable method of viral load measurement, which can significantly reduce transport difficulties as well as cost⁴⁻⁸. In addition, DBS requires a lesser volume of blood with reduced infectious risk making it safer to handle and also can be stored and transported at room temperature^{9,10}. Recent reports on the evaluation of DBS in resource-limited settings from Sub-Saharan Africa show promising trends^{6,11,12}. DBS has not been utilized or evaluated systematically in India. The present study was, therefore, conducted to compare the feasibility and cost of DBS HIV-1 RNA quantification with standard plasma viral load measurement for HIV-infected individuals in India receiving antiretroviral therapy.

Material & Methods

Study settings and patients: The patients included in the study were aged between 18-60 years, had documented HIV-1 infection and were part of the larger HIVIND cohort¹³. The HIVIND is a randomized control trial (Trial registration: ISRCTN79261738). The study protocol and patient inclusion and exclusion criteria were mentioned elsewhere¹³. The specific sites included the Infectious Disease Clinic of St. John's Medical College Hospital, Bangalore (Site 1) and ART Centre, K.R. Hospital, Mysore (peripheral centre) (Site 2; 200 km away from site 1). Both sites were situated within tertiary care hospitals located in two cities in Karnataka State in southern India. The main laboratory was situated in site 1. Ethical approval of the study protocol was obtained from the ethics committees at both sites and patients were recruited after written

obtained informed consent. During summer season, between April and June 2011, a total of 125 whole blood samples (2 ml) from HIV-1 positive samples were collected in EDTA vacutainers from patients. Among the 125 samples, 73 were collected from site 1 and 52 from site 2 from therapy-naïve and experienced participants. Samples were selected based on the plasma viral load in three strata; viral load (VL) 150 to 1000 copies/ml (n=30), VL 1000 to 5000 copies/ml (n=20) and VL>5000 copies/ml (n=56). Samples with VL not detected (n=19) were also included in the analysis. In addition, samples were collected from 5 HIV-1 uninfected individuals to serve as true negatives in every run to check for cross-contamination.

Preparation of DBS: Dried blood spot strips were prepared by spotting 50 µl of whole blood onto a Whatman 903 filter paper (3 spots per card). In site 1, filter papers were air dried overnight at room temperature and stored at 4°C in plastic sealed bag with a silica desiccant until they were processed. In site 2, collection and spotting of the DBS occurred in a similar fashion; however, after air drying overnight the DBS strips were stored at room temperature (Temperature: 30 to 35°C and humidity 71 to 82%) until transport. The DBS strips were transported at regular intervals (every 15 to 20 days) in plastic sealed bags at room temperature, followed by storage at 4°C until assay performance.

Preparation of plasma: Whole blood was centrifuged at 800 x g for 15 min, and plasma was extracted, aliquoted and stored at -20°C. Plasma samples separated in the peripheral centre were stored at -20°C and were transported to the primary laboratory in dry ice and stored at -80°C until analysis.

Plasma viral load: Plasma viral load was determined by Abbott Real Time PCR (RT-PCR) m2000rt system (Abbott Molecular, Germany), using manual RNA extraction procedure as per manufacturer's instructions. In short, plasma was treated with mLysis buffer (provided with Abbott RNA sample preparation system) to lyse the viral coat and release the nucleic acid. The armoured internal control was added to the lysis buffer before the treatment of the plasma. The lysed viral and internal control RNA was captured on magnetic beads followed by several washing steps to remove contaminants and inhibitors of RNA. Pure RNA was then eluted and detected using quantitative real-time RT-PCR. The internal control ensured correct extraction and non-inhibition of the RT-PCR reaction.

The assay detects a dynamic range of viral load ranging from 40 to 10,000,000 copies/ml. Quality control of the assay was maintained by certification from Quality Control for Molecular diagnostics (www.qcmd.org, Glasgow, Scotland).

DBS viral load: Dried blood spot viral load was measured as described previously with modifications⁴. Briefly, two blood spots from the same patient were punched out using a sterile puncher, and placed into 1.7 ml of mLysis buffer provided with the Abbott sample preparation system (m2000sp) in 50 ml sealed conical tubes. The tubes were incubated at room temperature for 2 h, with intermittent mixing. RNA was extracted manually from the lysate according to the standard HIV-1 RNA 1.0 ml extraction protocol using Abbott RNA sample preparation system. The viral load was measured from the extracted RNA using “m2000 DBS HIV-1 RNA ‘open-mode’ protocol” (Abbott Molecular, Germany). Laboratory researchers analysing the DBS were blinded about the true plasma viral load values.

Statistical analysis: Viral load was stratified into three levels: (i) VL 2.17 to 3 log₁₀ copies/ml (corresponding to 1000 copies/ml), (ii) VL >3 to 3.7 log₁₀ copies/ml, (1000- about 5000 copies/ml), and (iii) VL >3.7 log₁₀ copies/ml (corresponding to approximately 5000 copies/ml). Sensitivity and specificity of DBS viral load using plasma assay as the gold standard was assessed at all three viral load strata. Pearson correlation analysis was performed, as well as Bland-Altman analysis¹⁴ to examine the level of agreement between the two tests. Bland-Altman analysis was performed using MedCalc version 9.5.0.0 (MedCalc Software, Mariakerke, Belgium). With the given sample size that was used for Bland Altman analysis, the 95% CI for the limits of agreement were +/- 0.11 log₁₀ copies/ml. This narrow range in the precision of the limits of agreement was deemed to be clinically acceptable. In addition, the costs incurred for viral load estimation from the DBS and plasma were assessed and compared. For both the assays, costs considered included sample collection (filter paper and vials), envelopes, transport by courier (with cold chain maintenance for plasma and regular surface mail for DBS), laboratory consumables, external quality control, power consumption and real-time PCR assay including instrument cost, reagent cost and labour cost as per the prevailing retail price in India in July 2011 and for an assumed testing volume of approximately 1000 samples/year.

Results

Plasma viral load was obtained from a total of 125 individuals, and included those who were ART naive (n=54); individuals recently initiated on ART, (n=71; 50 at 4 wk and 21 at wk 24 after ART initiation) and 5 HIV-uninfected individuals. Among HIV-infected individuals, 106 (84.8%) had detectable plasma viraemia ranging from 150 to 6,613,818 copies/ml and 19 (15.2%) had undetectable viraemia (viral load <150 copies/ml).

Sensitivity and specificity analysis: Among samples where plasma viral load was >3.7 log₁₀ copies/ml (n=56) the DBS assay had a sensitivity of 100 per cent and a specificity of 100 per cent. DBS sensitivity was 90 per cent for samples with plasma viral load ranging from >3 to 3.7 log₁₀ copies/ml (n=20). Among samples with plasma viral load levels of 2.17 to 3 log₁₀ copies/ml (n=30), sensitivity of DBS was low at 50 per cent although specificity remained 100 per cent.

Correlation and Bland-Altman analysis: Of the 125 samples, 74 plasma-DBS pairs with detectable viral load in both the assays with >3 log₁₀ copies/ml viral load were included in the analysis. There was a positive correlation between the two assays with a Pearson correlation coefficient of r=0.96; P<0.05 (Fig. 1). A good correlation was observed between the DBS and plasma viral load values from samples obtained in both the sites (site 1: r=0.96; P<0.05 and site 2: r=0.97; P<0.05). Bland-Altman plots for samples with the clinically relevant viral load threshold values of >3.7 log₁₀ copies/ml (~5,000 copies/ml) (n=56) showed good level of agreement with a mean difference (bias) of 0.29 log₁₀ copies/ml with acceptable limits of agreement (-0.21 and +0.8 log₁₀ copies/ml) (Fig. 2). Overall, 80.4 per cent (45/56) of the samples had DBS values which differed less than 0.5 log₁₀ units¹⁵ compared to the corresponding plasma viral load value. This difference is clinically acceptable¹⁵. Among the remaining 11 samples, the highest difference was 0.75 log₁₀ copies/ml, which still remains within the clinically acceptable range.

Cost description: The total cost for DBS viral load and plasma viral load in the study setting at prevailing rates was calculated as \$ 47.60 (₹2,123) and \$ 50.27 (₹2,242) respectively (Table). Costs of plasma transport varied within States and between States, and ranged between \$ 2.94-3.08 (₹131-137) per sample. The overall cost incurred for testing of the DBS was \$ 2.67 (₹119) less




Fig. 1. Correlation between HIV-1 viral loads measured with the Abbott Real-Time m2000rt assay in dried blood spot (DBS viral load; y-axis) and liquid plasma (Plasma viral load, x-axis) samples. Each data point represents one of the 74 individual study samples with viral load $>3 \log_{10}$ copies/ml. The Pearson correlation coefficient was 0.96 ($P < 0.05$).




Fig. 2. Bland-Altman plot with 95% CI of limits of agreement between HIV-1 viral loads measured with the Abbott Real-Time m2000rt assay in dried blood spot and liquid plasma samples $>3.7 \log_{10}$ copies/ml ($n=56$). Results indicated a good limit of agreement with -0.21 and $+0.80 \log_{10}$ copies/ml (mean ± 2 SD). The mean difference or bias was $0.29 \log_{10}$ copies/ml.

per test compared to direct plasma viral load testing. Cost savings included those incurred for cold chain transportation and other logistics such as electricity and containers for transport required for plasma viral load.

Table. Cost comparisons of viral load determination by Abbott m2000rt system from plasma and dried blood spot specimens. Prices listed here represent the prevailing Indian values as of July 2011. Basic equipment costs available in laboratory were excluded as this was common to both types of assays

Parameters	Plasma viral load/ test (₹)*	Dried blood spot viral load/test (₹)*
Sample collection	00.28 (12)	01.26 (56)
Storage	00.42 (19)	00.00 (0)
Mean transportation cost	03.28 (146)	00.05 (2)
Instrumentation (RT) and AMC	11.60 (157)	11.60 (517)
Labour	01.19 (53)	01.19 (53)
Reagents and consumables	32.46 (1448)	32.46 (1448)
Quality control	01.00 (45)	01.00 (45)
Electricity consumption	00.04 (2)	00.04 (2)
Total	50.27 (2242)	47.60 (2123)

*Number shown represent cost in US dollars. Numbers in parentheses represent cost in Indian rupees

Discussion

Our results showed a significant correlation between plasma and DBS viral load measurement. Moreover, for viral load values $>3.7 \log_{10}$ copies/ml (>5000 copies/ml); 80.4 per cent of samples had less than $0.5 \log_{10}$ difference, and none exceeded a difference of $0.75 \log_{10}$ copies/ml, suggesting that DBS is a reliable method for detecting clinically significant virological failure.

The use of dried blood spot specimens as a source for diagnostic tests has become increasingly popular in recent years. DBS has been used to identify genetic and metabolic disorders in neonates¹⁶, detection of HIV-1 antibody¹⁷ and HIV-1 DNA for infant diagnosis of HIV infection¹⁸. The WHO has recommended the use of DBS for HIV drug resistance (HIVDR) surveillance for monitoring transmitted drug resistance in resource-limited settings¹⁹. The reasons for the tremendous popularity of DBS as a method of sample collection storage and analysis can be understood when one considers the numerous advantages with this method. In regions of limited expertise and infrastructure and non-reliable functioning of the cold chain for transport, DBS can be prepared by spotting whole blood onto a filter paper, either from venous blood or directly from a

finger prick, and transported at ambient temperature by road or via the postal system to the reference laboratory for analysis. In addition, DBS requires less sample volume and also has reduced biohazard risk that makes this an ideal method of transport.

Recent studies indicate that viral load measurement using plasma and DBS are comparable, although this is dependent on the RNA extraction method used^{4,20,21}. Many of these studies had been conducted in controlled conditions in reference laboratories in high-income settings in Europe and United States with automated RNA extraction processes which may not be feasible in basic laboratories in resource-limited settings. In a study using Abbott m2000rt system and automated RNA extraction procedure conducted by Marconi *et al*⁴ in Italy, paired DBS and plasma specimens with viral load levels ranging between 200 to >100,000 copies/ml were used revealing a sensitivity of 97 per cent; and 78.5 per cent pairs differed from each other by less than 0.5 log₁₀ copies/ml. A Spanish study conducted by Garrido *et al*⁵ with manual RNA extraction showed a DBS sensitivity of 75.3 per cent, with only 51.9 per cent samples have a difference of < 0.5 log₁₀ viral load. In our study, two thresholds were considered; viral load of 1,000 copies/ml (log₁₀ 3.0 copies/ml) which is often used as the cut-off for genotyping²² and 5,000 copies/ml (log₁₀ 3.7 copies/ml) which is the WHO threshold for definition of virological failure for individuals on first-line ART and needing to switch to second-line therapy^{15,23}. The high sensitivity and specificity of DBS viral load measurement achieved in our study was concordant with previous findings^{4-8,12}, which precludes the possibility of missing patients with virological failure who are eligible for second-line therapy as per the WHO guideline²³. Moreover, the positive correlation of DBS with plasma viral load at these thresholds, with good limits of agreement and minimal bias suggests that DBS is a reliable method for clinical interpretation of virological failure.

Other published studies have also indicated the feasibility of HIV-1 viral load quantification using DBS in varied settings with differing climatic and storage conditions, using an array of different commercial assays in resource-limited settings in Sub Saharan Africa and Asia²⁴⁻²⁶. Previously, HIV-1 RNA quantitation from DBS has shown good stability under different temperature and storage conditions ranging from ambient to -70°C^{4,7,12}. In our study, site 1 had ideal DBS collection and storage facilities, while site 2 was a setting with very basic laboratory

facilities where DBS samples were stored at room temperature and relatively high humidity for a mean duration of 18 days, and then transported to the central laboratory for viral load measurement. Despite the less than ideal conditions at site 2 (DBS stored at room temperature), there was good correlation of plasma and DBS viral load measurements for the samples with detectable viral load. Previous studies from other parts of the world have also supported the robustness of DBS when stored at room temperature^{8,12,27}. India is a tropical country with varied climatic conditions and the summer temperature can be very high. The recommended storage temperature for DBS continues to be 4°C, until further multicentric studies evaluate the efficacy of viral load monitoring by DBS stored at different temperatures in different climatic conditions in India.

The reduction in cost for DBS samples compared to direct plasma viral load testing can be substantial when applied at a national scale. With a cost reduction of \$2.67 (₹119) per test, the substitution of DBS testing for annual viral load assessment of approximately 400,000 individuals, the Indian public health system can save over \$ 1,000,000 (₹44,600,000) per year. In India, second-line ART is available at several centres around the country, where patients failing first-line ART are first assessed for virological failure before switching regimens. Even at the current rate of virological testing for potential failures (approximately 10,000 tests per year), the cost savings with substitution of DBS for direct plasma viral load testing would amount to over \$ 25,000 (₹1,115,000) a year²⁸.

Our study was limited geographically to southern India, a high-prevalence area with a predominance of subtype C virus. The non-inclusion of samples from other areas in India, particularly north-eastern areas where there is a greater prevalence of HIV-1 circulating recombinant forms, as well as hepatitis C co-infection may decrease the generalizability of our results. The relatively small sample size included in this study may also limit the accuracy of the results, however, significant correlation and limits of agreement of the two assay methods found in the study reinforce the usefulness and feasibility of utilizing DBS as a method for clinical viral load monitoring of patients on ART in India. Although the performance of DBS decreased at the lower viral load values (150 to 1,000 copies/ml), the correlation at the higher viral load values underscores the value of DBS as a feasible clinical monitoring tool. One limitation of the DBS method noted previously

by investigators suggest that the proviral DNA present in peripheral blood mononuclear cells can contribute towards a falsely high DBS viral load value⁸. However, our study has not revealed this, and higher DBS values have been noted in samples with viral load levels <3.7 log₁₀ copies/ml, but not in the >3.7 log₁₀ copies/ml group. Further, the dedicated “m2000 DBS HIV-1 RNA open-mode protocol” for DBS viral load in Abbott m2000rt system uses a constant correction factor which is highly reproducible⁴ and can overcome the interference of proviral DNA in viral load measurement.

In conclusion, our results suggest that the usefulness, feasibility and cost advantage of measuring viral load from DBS samples in tropical climatic conditions in India make DBS as an alternative sampling method for viral load monitoring in resource-limited settings specifically from the rural and remote parts of the country. Further studies of operational research to apply these findings within a clinical setting on a large scale will be useful in translating these findings into policy that will benefit India and the global community.

Acknowledgment

The study has been partially funded by a grant from European Union Framework Program 7.

References

1. People alive and on ART, National AIDS Control Organization, May 2011. Available from: http://www.nacoonline.org/upload/HIV%20data/Patients%20%20alive%20on%20ART%20_May%202011.pdf, accessed on June 1, 2011.
2. Ledergerber B, Lundgren JD, Walker AS. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. *Lancet* 2004; 364 : 51-62.
3. Bahrani A, Ramaswamy R, Oldfield EC. Effects of virologic rebound on CD4 cell counts. *Clin Infect Dis* 2001; 32 : 1231-2.
4. Marconi A, Balestrieri M, Comastri G, Pulvirenti FR, Gennari W, Tagliazucchi S, *et al.* Evaluation of the Abbott real-time HIV-1 quantitative assay with dried blood spot specimens. *Clin Microbiol Infect* 2008; 15 : 93-7.
5. Garrido C, Zahonero N, Corral A, Arredondo M, Soriano V, Mendoza C. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. *J Clin Microbiol* 2009; 47 : 1031-6.
6. Mbida AD, Sosso S, Flori P, Saoudin H, Lawrence P, Monny-Lobé M, *et al.* Measure of viral load by using the Abbott Real-Time HIV-1 assay on dried blood and plasma spot specimens collected in 2 rural dispensaries in Cameroon. *J Acquir Immune Defic Syndr* 2009; 52 : 9-16.
7. Brambilla D, Jennings C, Aldrovandi G, Bremer J, Comeau AM, Cassol SA, *et al.* Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision and RNA stability. *J Clin Microbiol* 2003; 41 : 1888-93.
8. Johannessen A, Garrido C, Zahonero N, Sandvik L, Naman E, Kivuyo SL, *et al.* Dried blood spots perform well in viral load monitoring of patients who received antiretroviral treatment in rural Tanzania. *Clin Infect Dis* 2009; 49 : 976-81.
9. Comeau AM, Pitt J, Hillyer GV, Landesman S, Bremer J, Chang BH, *et al.* Early detection of human immunodeficiency virus on dried blood spot specimens: sensitivity across serial specimens. Women and Infants Transmission Study Group. *J Pediatr* 1996; 129 : 111-8.
10. Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, Peeters M, *et al.* World Health organization/HIVResNet Drug Resistance Laboratory Strategy. *Antiviral Ther* 2008; 13 (Suppl 2): 49-57.
11. Waters L, Kambugu A, Tibenderana H, Meya D, John L, Mandalia S, *et al.* Evaluation of filter paper transfer of whole blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. *J Acquir Immune Defic Syndr* 2007; 46 : 590-3.
12. Kane CT, Ndiaye HD, Diallo S, Ndiaye I, Wade AS, Diaw PA, *et al.* Quantitation of HIV-1 RNA in dried blood spots by the real-time NucliSENS EasyQ HIV-1 assay in Senegal. *J Virol Methods* 2008; 148 : 291-5.
13. De Costa A, Shet A, Kumarasamy N, Ashorn P, Eriksson B, Bogg L, *et al.* Design of a randomized trial to evaluate the influence of mobile phone reminders on adherence to first line antiretroviral treatment in South India - the HIVIND study protocol. *BMC Med Res Methodol* 2010; 10 : 25.
14. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986; 307 : 307-10.
15. Technical Brief on HIV Viral Load Technologies (June 2010). Available from: http://www.who.int/hiv/topics/treatment/tech_brief_20100601_en.pdf, accessed on March 18, 2011.
16. McCabe ER, Huang SZ, Seltzer WK, Law ML. DNA microextraction from dried blood spots on filter paper blotters: potential applications to newborn screening. *Hum Genet* 1987; 75 : 213-6.
17. Hoff R, Berardi VP, Weiblen BJ, Mahoney-Trout L, Mitchell ML, Grady GF. Seroprevalence of human immunodeficiency virus among childbearing women. Estimation by testing samples of blood from newborns. *N Engl J Med* 1988; 318 : 525-30.
18. Cassol SA, Lapointe N, Salas T, Hankins C, Arella M, Fauvel M, *et al.* Diagnosis of vertical HIV-1 transmission using the polymerase chain reaction and dried blood spot specimens. *J Acquir Immune Defic Syndr* 1992; 5 : 113-9.
19. WHO manual for HIV drug resistance testing using dried blood spot specimen, March 2010. Available from: http://www.who.int/hiv/topics/drugresistance/dbs_protocol.pdf, accessed on March 12, 2011.
20. Franssen K, Mortier D, Heyndrickx L, Verhofstede C, Janssens W, Van der Groen G. Isolation of HIV-1 RNA from plasma: evaluation of seven different methods for extraction (part two). *J Virol Methods* 1998; 76 : 153-7.

21. Ssebugenyi I, Kizza A, Mpoza B, Aluma G, Boaz I, Newell K, *et al.* Comparison of the Abbott m2000 HIV-1 Real-Time and Roche AMPLICOR Monitor v1.5 HIV-1 assays on plasma specimens from Rakai, Uganda. *Int J STD & AIDS* 2011; 22 : 373-5.
22. Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, *et al.* Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. *J Antimicrob Chemother* 2011; 66 : 1886-96.
23. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach.– 2010 rev. July 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf, accessed on July 11, 2011.
24. Johannessen A. Dried blood spots in HIV monitoring: applications in resource-limited settings. *Bioanalysis* 2010; 2 : 1893-908.
25. Hamers RL, Smit PW, Stevens W, Schuurman R, Rinke de Wit TF. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. *Antivir Ther* 2009; 14 : 619-29.
26. Bertagnolio S, Parkin NT, Jordan M, Brooks J, Garcia-Lerma JG. Dried blood spots for HIV-1 drug resistance and viral load testing: A review of current knowledge and WHO efforts for global HIV drug resistance surveillance. *AIDS Rev* 2010; 12 : 195-208.
27. Pirillo MF, Recordon-Pinson P, Andreotti M, Mancini MG, Amici R, Giuliano M. Quantification of HIV-RNA from dried blood spots using the Siemens VERSANT HIV-1 RNA (kPCR) assay. *J Antimicrob Chemother* 2011; 66 : 2823-6.
28. National AIDS Control Program, Phase III (2006-2011), November 2006. Available from: www.nacoonline.org, accessed on July 13, 2011.

Reprint requests: Dr Anita Shet, Department of Pediatrics, St. John's Medical College & Hospital, St. John's National Academy of Health Sciences, Sarjapur Road, Bangalore 560 034, India
e-mail: anitashet@gmail.com